Ring chromosome X is one of the rarest with some unique phenotypical features in Turner syndrome. A young female presented to us with anasarca developed over the past 2 months due to congestive cardiac failure along with jaundice and orthopnea. She had growth retardation, intellectual disability, primary amenorrhea, lack of secondary sexual character development and dysmorphic features like low posterior hairline, shield chest and cubitus valgus. She had dilated cardiomyopathy (DCM) with intracardiac thrombus on echocardiography. Skeletal survey revealed short fourth metacarpal/tarsal on limbs. Karyotyping showed a mosaic pattern, with 45, X/46, X,r(X)(p22.3q28), i.e. Turner syndrome karyotype with ring chromosome. Her heart failure with reduced ejection fraction was managed with vasopressor along with anticoagulant and given oral contraceptive pills for hormone replacement therapy. The ring chromosomal pattern of karyotype in this patient and DCM is a rare cardiological phenomenon that can be associated with Turner syndrome, making this case a unique one.
Sagittal T1-weighted magnetic resonance imaging of left foot showed geographic lesions in the lower tibia, talus, and calcaneum (arrows).
Objectives Cutaneous polyarteritis nodosa (CPAN) is a distinct clinical entity represented by a chronic, relapsing, benign course with a rare systemic involvement [1]. Treatment is with steroids, cyclophosphamide or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDS)[2]. In this case series, we aimed to share our varied clinical experience of successfully treating patients with CPAN, with tofacitinib in refractory/relapsing course as well as upfront monotherapy without steroids/csDMARDS. Methods We report this retrospective case series managed at our rheumatology centre in Bangalore from 2019–2022. Four patients identified as CPAN on biopsy were able to achieve disease-free remission with tofacitinib as part of treatment, with no relapse on further follow up. Our patients presented with subcutaneous nodules and cutaneous ulcers. After systemic evaluation, all the patients underwent skin biopsy which showed fibrinoid necrosis in the vessel walls of the dermis with histopathological impression of CPAN. They were initially treated with a conventional approach of steroids with/without csDMARDS. On experiencing a refractory/relapsing course, Tofacitinib was tried in all the patients as either steroid sparing/upfront monotherapy without concomitant csDMARDS. Results Use of tofacitinib resulted in improvement of ulcers and paresthesia, and gradual healing of skin lesions, although with scarring, with no further recurrence or relapse over a period of follow-up of 6 months for all the patients. The therapeutic effect of tofacitinib was consistent when used either as steroid sparing or as upfront monotherapy thereby proving the drug to be a promising option that warrants larger trials in future to treat the subset of patients with established CPAN. Conclusion Tofacitinib could be used for disease-free remission as monotherapy for Cutaneous polyarteritis nodosa either upfront or as steroid-sparing, even without concomitant csDMARDS, in those patients who are dependent on steroids or multiple DMARDs. Lay summary What does this mean for patients? Cutaneous polyarteritis nodosa (CPAN) is a rare disease that causes frequently recurring and often chronic skin lesions. Steroids and other drugs are used to treat it, but some patients may not respond well or may have side effects. In this case series, it was found that tofacitinib, a medication used to treat people with rheumatoid arthritis, was effective in treating CPAN in four patients. When we followed up with the patients, they had achieved disease-free remission with no relapse. Some patients were able to stop taking steroids and other drugs after starting tofacitinib. It is hence suggested that tofacitinib could be used as a monotherapy (i.e. without combining it with other drugs) for CPAN to reduce the need for steroids and other drugs. It is hoped that future researchers will find these data encouraging and may conduct larger trials to investigate the use of tofacitnib to treat CPAN.
A man in his 60s developed reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin (iBCG) for papillary carcinoma of bladder. Evaluation revealed leucocytosis and raised inflammatory markers. HLA B27 was positive. Based on the temporal relationship, it was attributed to BCG-related reactive arthritis. iBCG was stopped. Treatment with non-steroidal anti-inflammatory drugs (NSAIDS) and glucocorticoids were ineffective. Prolonged course of disease-modifying antirheumatic drugs (DMARDS) was required which aided in alleviation of symptoms and sustained remission. Intravesical BCG therapy is a treatment for bladder cancer. It is rarely associated with reactive arthritis, which responds to discontinuation of iBCG and treatment with NSAIDS and/or short-term glucocorticoids. iBCG-related reactive arthritis commonly has an acute/subacute course. Chronic arthritis as observed in our case requiring prolonged treatment with DMARDS is rare.
Pyoderma gangrenosum (PG) is a rare autoinflammatory disorder falling under the spectrum of neutrophilic dermatosis, characterized by distinctive skin ulceration which is non‐infective, non‐neoplastic and usually with no primary vasculitis. PG lesions are notorious for relapse and hence require multiple trials of medications often with prolonged and concomitant use of steroids. Due to lack of evidence‐based studies on effective treatment options for PG, we have presented three isolated biopsy‐proven PG cases who were successfully treated with Tofacitinib, a Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway inhibitor, without relapse in follow up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.